Global Induced Pluripotent Stem Cells Production Market by Product Type (Instruments/Devices, Automated Platforms, Consumables & Kits, Services)
Industry: Healthcare
Published Date: December-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 250
Report ID: PMRREP33244
Newly-released Induced Pluripotent Stem Cells Production industry analysis report by Persistence Market Research shows that global sales of Induced Pluripotent Stem Cells Production in 2021 was held at US$ 949.6 Mn. With a CAGR of 10.7% during 2022 - 2032, the market is projected to reach a valuation of around US$ 3 Bn. Consumables & Kits is expected to be the highest revenue-generating Product type with a CAGR of 12.2% during the forecast period.
|
Attribute |
Details |
|
Global Induced Stem Cells Market (2022) |
US$ 1 Bn |
|
Global Induced Stem Cells Market (2032) |
US$ 2.9 Bn |
|
Global Induced Stem Cells Market CAGR (2022 – 2032) |
10.7% |
|
U.S. Induced Stem Cells Market (2022) |
11.4% |
|
Key Companies Profiled |
|
As per the Induced Pluripotent Stem Cells Production industry research by Persistence Market Research - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the Induced Pluripotent Stem Cells Production industry increased at around 9% CAGR. Countries such as the U.S., China, Japan, the U.K., and South Korea held a significant share of the global market.
Increased demand for these cells, increased focus on research, and their potential application in the treatment of various diseases are driving the worldwide market. The increased prevalence of chronic diseases such as diabetes, heart disease, stroke, and cancer is fueling market expansion. Furthermore, expanding public awareness of stem cells and related research, prospective clinical uses, and government and private sector financial support are projected to contribute considerably to market growth.
The iPSC approach is expected to be widely used in the pharmaceutical sector to generate effective cell sources such as iPSC-derived functional cells for drug screening and toxicity assessment. Owing to this, the Induced Pluripotent Stem Cells Production market is projected to grow at a CAGR of 10.7% over the coming 10 years.
Pluripotent stem cells are embryonic stem cells that can develop into any adult cell type and help the body mend damaged tissues. Induced pluripotent stem cells (iPSCs) are pluripotent stem cells or embryonic stem cells that have been genetically altered to function like pluripotent stem cells or embryonic stem cells.
They can be extracted from any tissue of a child or an adult. The market for induced pluripotent stem cells is growing, owing to their ability to produce any cell or tissue the body requires. These cells can potentially be customized to provide a perfect genetic match for any patient suffering from diseases such as diabetes, spinal cord injury, leukemia, or heart disease.
Furthermore, these cells may be used to learn about the earliest stages of human development and can be used to build personalized, rejection-proof cells and tissues for transplantation. Furthermore, the public and commercial sectors are boosting financing and expanding the industry that focuses on various research projects including iPSCs, and people are becoming more aware of stem cells as a result of many organizations.
However, problems such as expensive cell reprogramming, ethical concerns, and long processes are stifling the market's growth. Low efficiency, tumor risk, and insufficient programming are all challenges that are restricting the expansion of the iPSC business.
Induced pluripotent stem cells (iPSCs) offer various benefits over Embryonic Stem Cells (ESCs), including the ability to circumvent the ethical issues connected with stem cells and the most versatility in cell-based research applications. Induced pluripotent stem cells (iPSCs) have gained tremendous traction in recent years because of these benefits, generating a favorable market for players in the field.
The market is expected to increase faster because of the rich pipeline for iPSC-derived cell therapies and new iPSC applications. The overall number of iPSC clinical studies is expected to reach 54 by the year 2021. Allele Biotechnology & Pharmaceuticals, for example, is working on a diabetic medication generated from iPSC-derived pancreatic beta cells.
COVID-19 boosted interest in iPSC-based research and development. Researchers are also eager to discover new cures and treatments to tackle the epidemic. In this context, iPSCs are effective research tools for producing normal cell types that are relevant to the SARS-CoV-2 virus. Furthermore, iPSCs are critical for creating physiologically relevant human-cell models that may mimic COVID-19 pathology and so improve medication testing.
A study team at Newcastle University in the United Kingdom, for example, has produced a lung cell model from iPSCs that may be used to better understand how SARS-CoV-2 infects the airways. High iPSC manufacturing costs, as well as tumorigenicity, immunogenicity, and heterogeneity, might stymie industry expansion.
In-vitro growth of iPS cells may result in chromosomal instability, loss of heterozygosity, copy number variants, and genetic instability. Furthermore, iPSCs are often manufactured and extended using a feeder layer method, which can lead to significant lot-to-lot variability, safety, and regulatory problems, and a reduction in process scalability.
Which Region is projected to Offer the Largest Opportunity for Induced Pluripotent Stem Cells Production?
With an over 11% projected growth rate, Induced Pluripotent Stem Cells revenue is expected to grow at the fastest pace in North America during 2022 – 2032 with an absolute dollar growth of US$ 704.3 Mn.
Due to multiple mergers, partnerships, and acquisitions by major players in the area, North America is expected to maintain the dominating position in the worldwide Induced Pluripotent Stem Cells Production market post-pandemic.
The Induced Pluripotent Stem Cells Production Market in North America is expected to grow at a CAGR of 11.4% during the forecast period. The California Institute for Regenerative Medicine (CIRM) provides funding to research institutions for iPSC research and translation into clinical applications. The National Institutes of Health (NIH) has also launched the Regenerative Medicine Program.
This program's objective is to create materials that will help to accelerate the usage of iPSCs for therapeutic purposes. In addition, the RPM promotes the dissemination of iPS cell lines for clinical and laboratory research.
Over the projection period, Europe is expected to maintain moderate growth. The EBiSC's creation has sped up iPSC research in this area. The mission of the EBiSC is to provide disease-relevant, quality-controlled, research-grade iPS cell lines, data, and cell services to researchers. In addition, a non-profit iPS cell lines bank provides consistent, high-quality instruments for the creation of novel medicines for businesses and academia.
U.S. Induced Pluripotent Stem Cells Production Market Analysis
The market in the U.S. is expected to reach a valuation of US$ 1.1 Bn by 2032. During the forecast period, the market is projected to gross an absolute dollar opportunity of US$ 704.3 Mn growing at a CAGR of 11.4%.
U.K. Induced Pluripotent Stem Cells Production Market Analysis
The U.K. market is likely to garner an absolute dollar opportunity of US$ 80 Mn during the forecast period. Growing at a CAGR of 11.3% during the forecast period, the market is likely to reach a valuation of US$ 123 Mn by 2032.
Japan Induced Pluripotent Stem Cells Production Market Analysis
In Japan, the market is expected to reach a valuation of US$ 114 Mn. With an absolute dollar opportunity of 80 Mn, the market in the country is expected to grow at a CAGR of 12.6% during the forecast period.
South Korea Induced Pluripotent Stem Cells Production Market Analysis
The market in South Korea is projected to reach US$ 64 Mn by 2032. Growing with a CAGR of 12%, the market in South Korea is expected to gross an absolute dollar opportunity of US$ 43 Mn during 2022 – 2032.
Which Product of Induced Pluripotent Stem Cells Production will be most preferred?
The market for consumables & Kits is expected to grow at a CAGR of 12.2%. They have been shown to yield more consistent iPSCs while reducing human bias and assuring procedure uniformity. Additionally, it gives an opportunity for cell reproducibility, lowers costs, boosts throughput, and provides the necessary flexibility for iPS cell line cultivation.
Which Induced Pluripotent Stem Cells Production Process will be Most Preferred?
The manual process is expected to grow fastest at a CAGR of 10.7% during the forecast period. With a revenue share of over 78% in 2020, the manual iPSC production process segment dominated the global market. By simply streamlining the manual methods commonly employed to reprogram patient cells, the iPSC generation process can be made more cost-effective and efficient.
Reprogramming somatic cells into iPS cells is mostly a manual procedure using a number of commonly used manual equipment and techniques. The manual iPSC creation procedure necessitates the use of competent workers who can detect eligible colonies and efficiently carry out various generation processes. It also provides a handy approach for simultaneously creating many iPSC lines, which has contributed to the segment's supremacy.
Some of the key players in the Induced Pluripotent Stem Cells Production market include Lonza, Axol Biosciences Ltd., Evotec, Hitachi Ltd., Merck KGaA, REPROCELL Inc., Fate Therapeutics, Thermo Fisher Scientific, Inc., StemCellFactory III, and Applied StemCell Inc.
Some of the recent developments of key Induced Pluripotent Stem Cells Production providers are as follows:
Similarly, the team at Persistence Market Research, which is available in the full report, has tracked recent developments related to companies offering Induced Pluripotent Stem Cells Production.
By Product Type
By Process
By Workflow
By Application
By Region
To know more about delivery timeline for this report Contact Sales
The Global Induced Pluripotent Stem Cells Production market is worth more than US$ 1 Bn at present.
The value of Induced Pluripotent Stem Cells Production is projected to increase at a CAGR of around 10.7% during 2022– 2032.
The value of Induced Pluripotent Stem Cells Production increased at a CAGR of around 9% during 2017 – 2021.
The key players in the Induced Pluripotent Stem Cells Production market are Lonza; Axol Biosciences Ltd.; Evotec; Hitachi Ltd.; Merck KGaA; REPROCELL Inc.; Fate Therapeutics; Thermo Fisher Scientific, Inc.; StemCellFactory III; and Applied StemCell Inc.
The top 5 countries driving demand for Induced Pluripotent Stem Cells Production are the U.S., China, Japan, the U.K., and South Korea.
U.S. will account for over 38% of global Induced Pluripotent Stem Cells Production demand in 2032 with a CAGR of 11.4%.
The market for Induced Pluripotent Stem Cells Production is projected to expand at a CAGR of around 10.7% during 2022 – 2032 with a global market size of US$ 2.9 Bn.
While the market in South Korea is expected to grow at nearly 12%, the market in Japan is projected to register a CAGR of nearly 12.6% during 2022 - 2032.
